Anti-VEGF for RVO: The Gold Standard

John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.

Related Content:

Shaping the Future of Retinal Vascular Disease Treatment

Faricimab for DME: Durability and Patient Outcomes

Faricimab for nAMD: Key Trial Highlights and Case Example

Overview of Real-World Outcomes for nAMD, DME, and RVO Patients